Participant flow



Baseline characteristics

Table 1: Study subject demographics.

Demographics	Young	Older
n	30	36
Gender		
Males	10	16
Females	20	20
Age (y), median (IQR)	30 (26-38)	83 (75-87)
Weight (kg), median (IQR)	72 (64-85)	77 (69-89)

Outcome measures

Table 2: Haematological parameters at baseline and in the presence of rivaroxaban and statistical test results for the two subject groups.

Rivaroxaban concentration (ng/ml)	*mean (SD)*		t-test	Regression models	
	Young	Elderly	**p-value**	**p-value**	R-sq (%)
PT (s)					
0	11.6 (1.1)	11.9 (0.9)	0.022		
100	15.1 (1.2)	16.7 (1.6)			
250	20.2 (1.9)	23.8 (2.9)		< 0.001	90.76
400	26.2 (2.6)	30.9 (4.5)			
500	30.0 (2.5)	36.1 (4.5)			
mPT (s)					
0	38.7 (4.4)	45.4 (10.5)	< 0.001		
100	65.4 (9.5)	88.9 (17.9)			
250	105.6 (21.0)	151.1 (32.5)		< 0.001	79.86
400	155.9 (31.7)	212.6 (47.0)			
500	182.9 (36.6)	253.9 (55.7)			
FII activity (%)					
0	99.7 (15.3)	82.7 (17.8)	0.002		
100	79.1 (10.8)	64.5 (10.6)			
250	60.9 (9.3)	49.2 (8.8)		< 0.001	94.67
400	45.7 (7.3)	36.5 (5.2)			
500	38.3 (4.8)	30.9 (4.8)			
FX activity (%)					
0	89.7 (13.5)	85.5 (16.6)	0.281		
100	78.5 (13.2)	71.0 (13.8)			
250	64.5 (11.7)	57.6 (11.5)		< 0.001	94.99
400	53.6 (10.3)	46.4 (9.5)			
500	47.3 (8.8)	41.7 (8.7)			
aPTT (s)					
0	29.0 (2.6)	33.9 (7.9)	< 0.001		
100	36.5 (3.0)	42.1 (11.0)			
250	42.8 (5.0)	49.5 (13.3)		0.03	84.22
400	49.5 (5.3)	58.8 (20.2)			
500	53.8 (5.4)	63.8 (23.5)			

Table 3: Thrombin generation assay parameters, at baseline and with the presence of rivaroxaban (mean ± SEM).

		Lag time (min)	Peak (nM)	ttpeak* (min)	ETP ∂ (nM*min)	Velocity index (nM/min)
Baseline	*Young*	2.94 (0.07)	322.88 (8.23)	5.54 (0.11)	2396.90 (57.01)	127.71 (5.41)
	Elderly	3.31 (0.13)	263.93 (7.93)	6.43 (0.19)	1978.4 (63.87)	87.66 (4.78)
p-value		0,012	0,004	<0.001	0,001	<0.001
Rivaroxaban ^	*Young*	9.60 (0.21)	66.98 (4.15)	25.56 (0.74)	1682.16 (51.60)	4.75 (0.58)
	Elderly	11.58 (0.64)	41.34 (1.78)	29.12 (0.86)	1279.71 (38.32)	2.56 (0.24)
p-value		0,007	<0.001	<0.001	0,003	0,001

*ttpeak = time to peak; ∂ ETP = endogenous thrombin potential; ^ 187.5 ng/ml final concentration

Adverse events

There were no adverse events associated with this trial.